National Genetics Institute (NGI) gets go-ahead for hepatitis C test:
This article was originally published in Clinica
The National Genetics Institute has FDA permission to sell its Superquant hepatitis C test to assess the antiviral effects of new drugs to treat the condition. The test has been used in large-scale studies of two new drugs. It is the first test to be able to claim that it directly measures the effects of an HCV treatment.
You may also be interested in...
The addition of the question “Was this device serviced by a third party servicer?” to adverse event reports filed through the US FDA’s electronic Medical Device Reporting system could prove helpful for the agency and device makers, experts tell Medtech Insight. Industry has long complained about poor work performed by servicers – and loudly groused that they’re not regulated.
Attorneys tell Medtech Insight a recent proposal to review regulations every 10 years could lift some burdens from the medical device industry, but warned that the full effects may not be seen for some time.
A nasal spray formulated using compounds already approved by regulatory bodies in Europe and the US can “prevent and slow” transmission of COVID-19, according to UK researchers who are now seeking a partner to commercialize the product.